ArticleOncogene2006
A peptide aptamer to antagonize BCL-6 function.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 51 citations in OpenAlex.
- B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.Molecular cancer research : MCR · 2022Review
- The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- Detecting protein-protein interactions based on kinase-mediated growth induction of mammalian cells.Scientific reports · 2014Article
- Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2013Review
- Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers.Oncogene · 2011Article
- Peptide aptamers as new tools to modulate clathrin-mediated internalisation--inhibition of MT1-MMP internalisation.BMC cell biology · 2010Article
- Structure-function studies of an engineered scaffold protein derived from stefin A. I: Development of the SQM variant.Protein engineering, design & selection : PEDS · 2010Article
- Bcl6 is expressed in neuroblastoma: tumor cell type-specific expression predicts outcome.Translational oncology · 2009Article
- Structure of the wild-type human BCL6 POZ domain.Acta crystallographica. Section F, Structural biology and crystallization communications · 2008Article
- B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.Current opinion in hematology · 2008Review
- Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.Leukemia & lymphoma · 2008Review
- Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.Molecular cell · 2008Article
- Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands.Cancer science · 2008Review
- Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays.Journal of biology · 2008Article
- Article
- Synthesis and selection of de novo proteins that bind and impede cellular functions of an essential mycobacterial protein.Applied and environmental microbiology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
BCL-6 is a transcription factor essential for germinal centre B-cell development. The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer. BCL-6 is a transcriptional repressor whose N-terminal POZ domain mediates protein-protein interactions to exert its effects. Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48. Apt48 binds BCL-6 POZ in a manner distinct from the transcriptional corepressor SMRT, yet was found to prevent BCL-6-mediated repression of a luciferase reporter gene. Apt48 also reproduced several previously validated effects of BCL-6 inhibition. Notably, expression of the differentiation markers CD69, Blimp-1 and cyclin D2 was increased in B-cell lines when Apt48 was expressed. We also show that expression of Apt48 restores cytokine-mediated growth arrest to BCL-6 overexpressing cells. Thus, we have identified a peptide aptamer that affects a function of BCL-6 that is required to prevent differentiation of proliferating B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.